Mealey's (May 11, 2018, 1:09 PM EDT) -- WASHINGTON, D.C. — Mylan Laboratories Ltd. on April 24 defended a final written decision of the Patent Trial and Appeal Board, which deemed obvious various claims of an Aventis Pharma S.A. patent covering a method of using cabazitaxel to treat prostate cancer patients following treatment with docetaxel (Aventis Pharma S.A. v. Mylan Laboratories Ltd., No. 18-1203, Fed. Cir.)....